Chilean Pediatric Type 1 Diabetes Incidence Doubled Since 2007

Pediatric Type 1 Diabetes and the Post-Pandemic Clinical Landscape

The management of pediatric type 1 diabetes has evolved significantly with the integration of continuous glucose monitoring and insulin pump technologies, though these devices are associated with dermatologic complications such as contact dermatitis and lipodystrophies (localized changes in fat tissue distribution) [1]. Despite these advancements, acute complications such as diabetic ketoacidosis (a life-threatening state of metabolic exhaustion characterized by hyperglycemia and acidosis) remain a persistent threat to patient safety [2, 3]. Recent meta-analyses involving over 150,000 children indicate that the COVID-19 pandemic significantly altered disease presentation, with the risk of diabetic ketoacidosis increasing by 35% to 68% compared to pre-pandemic levels [4, 5]. Clinicians have observed a particularly sharp rise in severe metabolic decompensation at initial diagnosis, with one analysis of 124,597 patients showing a relative risk of 1.41 (95% CI 1.19, 1.67) for ketoacidosis among newly diagnosed cases [3]. Furthermore, the odds of requiring intensive care unit admission rose significantly (OR 1.90; 95% CI 1.60-2.26) during this period [4]. A new population-based analysis now provides a multi-year perspective on how these epidemiological shifts manifested within a national healthcare system.

Long-Term Epidemiological Shifts in Chile

The researchers conducted a population-based analysis using a nationwide registry of 9583 individuals aged less than 20 years who were diagnosed with type 1 diabetes in Chile between 2007 and 2023. This 16-year longitudinal dataset allowed for a precise calculation of annual and quarterly incidence rates across the country, providing a comprehensive view of the disease's trajectory before, during, and after the global pandemic. The findings demonstrate a substantial and steady upward trend in disease frequency over the study period. Specifically, the incidence of type 1 diabetes rose from 7.4 cases per 100,000 people aged less than 20 years in 2007 to 13.9 cases per 100,000 in 2023. This nearly twofold increase in the national incidence rate underscores a significant shift in the pediatric endocrine landscape that clinicians must navigate, suggesting that the underlying triggers for autoimmunity are becoming more prevalent in the general population.

Beyond the overall increase in cases, the study identified specific demographic and environmental factors associated with higher disease onset. When comparing averages by sex and age, the researchers found that incidence rates were significantly higher in the 10- to 14-year age group than in other pediatric cohorts. Furthermore, the data revealed a distinct temporal pattern in diagnosis, as average incidence rates were significantly higher during the winter months compared to other seasons. For the practicing physician, these peaks in the 10- to 14-year demographic (a period of rapid pubertal growth and hormonal flux) and during the winter season provide critical diagnostic context. These findings suggest that environmental triggers, such as seasonal viral infections or physiological changes during early adolescence, may contribute to the timing of clinical presentation, requiring heightened vigilance during these high-risk windows.

Quantifying the Pandemic Deviation

To determine whether the observed spike in type 1 diabetes cases was a continuation of existing trends or a distinct departure caused by the global health crisis, the researchers employed a seasonal autoregressive integrated moving average (SARIMA) model. This statistical method forecasts future data points by analyzing historical seasonal trends and accounting for cyclical fluctuations, allowing the authors to establish a predicted baseline of what the incidence rates would have been from 2020 onward if the prepandemic trajectory had remained constant. By comparing these projections against real-world data, the study could isolate the specific impact of the pandemic years on disease onset, effectively separating the background growth of the disease from the acute effects of the pandemic environment.

The analysis revealed that actual quarterly incidence rates were significantly higher than those predicted by the SARIMA model during the 2020 to 2021 period, confirming a substantial deviation from historical patterns. This surge suggests that the environmental or biological pressures present during the height of the pandemic, such as direct viral impact or significant lifestyle alterations, may have accelerated the clinical presentation of type 1 diabetes in susceptible children. However, this deviation was temporary. The researchers found that actual quarterly incidence rates were not significantly different from SARIMA predictions during the 2022 to 2023 period, indicating that the acute surge in new diagnoses had subsided. Following this period of heightened activity, the incidence rates returned to the prepandemic trend, suggesting that while the pandemic caused a sharp, immediate increase in cases, it did not permanently alter the long-term epidemiological trajectory of the disease in Chile.

Rising Clinical Severity at Presentation

Beyond the rising incidence rates, the researchers investigated whether the clinical presentation of the disease became more acute during the pandemic. To assess this, an individual pre-post analysis was performed on a clinical cohort of 334 patients aged less than 18 years. These patients were recruited from three tertiary centers between 2016 and 2023 to provide a detailed look at metabolic stability at the time of diagnosis. Among this specific group of 334 patients, 71% presented with diabetic ketoacidosis, a life-threatening state of metabolic decompensation characterized by hyperglycemia, ketonemia, and metabolic acidosis. This high baseline rate of ketoacidosis highlights the ongoing challenge of delayed diagnosis in pediatric populations, where early symptoms may be overlooked until the patient reaches a state of critical illness.

The data revealed a concerning shift in disease severity as the pandemic progressed. The proportion of patients presenting with diabetic ketoacidosis increased significantly from 64.3% during the 2016 to 2019 period to 75.9% between 2020 and 2023 (P = .03). This statistical increase suggests that children diagnosed during the pandemic were more likely to arrive at tertiary centers in a state of advanced metabolic crisis compared to those diagnosed in the preceding years. For the practicing clinician, these figures underscore a period where the window for early intervention was frequently missed, leading to more complex initial hospitalizations and potentially higher risks of long-term complications associated with severe initial metabolic insult.

The study concluded that the COVID-19 pandemic was associated with a significant increase in type 1 diabetes incidence paired with higher severity at onset. This dual burden of a higher volume of cases and more acute clinical presentations suggests that the pandemic environment may have both triggered the disease in susceptible individuals and delayed the recognition of early symptoms due to healthcare disruptions. While the incidence rates eventually returned to historical trends by 2022, the period between 2020 and 2021 remains a critical example of how global health crises can exacerbate the presentation of chronic pediatric conditions, reinforcing the need for robust screening and early diagnostic protocols during periods of societal stress.

References

1. Podwojniak A, Flemming J, Tan IJ, Ghani H, Neubauer Z, Jones A. Cutaneous Adverse Effects From Diabetes Devices in Pediatric Patients With Type 1 Diabetes Mellitus: Systematic Review.. JMIR dermatology. 2024. doi:10.2196/59824

2. Cherubini V, Rabbone I, Lombardo F, Mossetto G, Federici MO, Nicolucci A. Incidence of severe hypoglycemia and possible associated factors in pediatric patients with type 1 diabetes in the real-life, post-Diabetes Control and Complications Trial setting: A systematic review.. Pediatric diabetes. 2019. doi:10.1111/pedi.12876

3. Elgenidy A, Awad AK, Saad K, et al. Incidence of diabetic ketoacidosis during COVID-19 pandemic: a meta-analysis of 124,597 children with diabetes.. Pediatric research. 2023. doi:10.1038/s41390-022-02241-2

4. Meregildo-Rodriguez ED, León-Jiménez FE, Tafur-Hoyos BAD, Vásquez-Tirado GA. Impact of the COVID-19 pandemic on the incidence and clinical outcomes of diabetic ketoacidosis among male and female children with type 1 diabetes: systematic review and meta-analysis.. F1000Research. 2023. doi:10.12688/f1000research.128687.2

5. Alfayez OM, Aldmasi KS, Alruwais NH, et al. Incidence of Diabetic Ketoacidosis Among Pediatrics With Type 1 Diabetes Prior to and During COVID-19 Pandemic: A Meta-Analysis of Observational Studies.. Frontiers in endocrinology. 2022. doi:10.3389/fendo.2022.856958